Diagnostics and therapy of antineutrophil cytoplasmic antibody (ANCA) associated vasculitides

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4537-4541

  Reinhold Keller, Eva ^a  

^a Klinikum Bad Bramstedt   (Germany)

Author keywords

ANCA; Antineutrophil cytoplasmic antibody; Cyclophosphamide; Granulumatosis with polyangiitis (wegener's); Rituximab

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MEPOLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ADD ON THERAPY; ANCA ASSOCIATED VASCULITIS; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; KIDNEY BIOPSY; LABORATORY TEST; LEUKOPENIA; LOW DRUG DOSE; MICROSCOPIC POLYANGIITIS; MYELODYSPLASTIC SYNDROME; NEOPLASM; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; STEROID THERAPY; SYSTEMIC VASCULITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

CHURG-STRAUSS SYNDROME; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; RECURRENCE; REMISSION INDUCTION; WEGENER GRANULOMATOSIS;

EID: 84866409924     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502260     Document Type: Article

References (43)

1. Herlyn K, Hellmich B, Gross WL, Reinhold-Keller E. Stable Incidence of Systemic Vasculitides in Schleswig-Holstein, Germany. Dtsch Arztebl Int 2008; 105: 355-361.
2. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalence of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis and Churg Strauss syndrome in a Frenche urban multiethnic population in 2000, a capture-recapture estimate. Arthritis Care Res 2004; 51: 92-99.
3. Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46: 1329-1337
4. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-1107
5. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: The proposal of an International Consensus Conference. Arthritis Rheum 1994; 37: 187-192
6. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317.
7. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-1032.
8. Holle J, Gross WL, Latza U, et al. Improved outcome of 445 Wegener's granulomatosis patients in a German vasculitis center over four decades. Arthritis Rheum (in press) 2010.
9. Aasarod K, Bostad L, Hammerstrom J, Jorstad S, Iversen BM. Renal histopathology and clinical course in 94 patients with Wegeners granulomatosis. Nephrol Dial Transplant 2001; 16: 953-960.
10. Csernok E, Lamprecht P, Gross WL. Diagnostic significance of ANCA in vasculitis. Nat Clin Pract Rheumatol 2006; 2: 174-175.
11. Finkielman JD, Lee As, Hummel AM, Viss MA, Jacob GL, Homburger HA. ANCA are detectable in nearly all patients with active severe Wegeners granulomatosis. Am J Med 2007; 120: 643-647.
12. Pagnoux C, Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol 2010; 22: 21-28.
13. Chen M, Kallenberg CG. New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009; 27: 108-114.
14. Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010 May 28. [Epub ahead of print]
15. Sable-Fourtassou R, Cohen P, Mahr A. Antineutrophil cytoplasmic antibodies and the Churg Strauss syndrome. Ann Intern Med 2005; 143: 632-638.
16. Guillevin L, Duran-Gasselin B, Cevallos R. Microscopic polyangiitis: Clinical and laboratoy findings in 85 patients. Arthritis Rheum 1999; 42: 421-430.
17. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116(6): 488-498.
18. de Groot K, Harper L, Jayne DRW, et al. Pulse versus daily cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody associated vasculitis. Ann Intern Med 2009; 150:670-680.
19. Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188.
20. Jones RB, Cohen Tervaert JW, et al. Rituximab versus cyclpohosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 2111-2120.
21. Stone JH., Markel PA, Spier R, et al. Rituximab vs. cyclophosphamide for ANCA-accociated vasculites. N Engl J Med 2010; 363: 221-232.
22. Reinhold-Keller E, de Groot K, Rudert H, Noelle B, Heller M, Gross WL. Response to trimethoprim/sulfomethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 1996; 89: 15-23.
23. de Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-2469.
24. Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegeners granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000; 43: 1841-1848.
25. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
26. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Gross WL. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus Trimethoprim/Sulfamethoxazole. Arthritis Rheum 1996; 39: 2052-2061.
27. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis. Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-2673.
28. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 463-469.
29. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326-332.
30. Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007; 86: 269-277.
31. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1087-1091.
32. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-2803.
33. Flossmann O, de Groot K. When should patients with ANCAassociated vasculitis be switched from induction to maintenance therapy? Nat Clin Pract 2007; 3: 236-237.
34. Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147: 611-619.
35. Walsh M, Merkel PA, Mahr A, Jayne D. The effects of duration of glucocorticoid therapy on relapse rate in anti-neutrophil cytoplasm antibody associated vasculitis: A meta-analysis. Arthritis Care Res 2010; 62: 1166-1173.
36. Harper L, Savage COS. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000; 190: 349-359.
37. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor blockade in Wegeners granulomatosis. Ann Rheum Dis 2005; 64: 31-36.
38. Gause A, Arbach O, Lamprecht P. Treatment of primary systemic vasculitis with TNF-antagonists. Z Rheumatol 2003; 62: 228-234.
39. The Wegener granulomatosis Etanercept (WGET) Research Group. Etanercept plus standard therapy for Wegeners granulomatosis. N Engl J Med 1005; 352: 351-361.
40. Keogh K, Wylam M, Stone J, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 2005; 52: 262-268.
41. Jones RB, Ferraro AJ, Chaudhry AN. A multicenter survey of Rituximab therapy for refractrory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168.
42. Metzler C, Schnabel A, Gross WL, Hellmich B. Aphase Ii study of interferon alpha for the treatment of refractory Churg Strauss syndrome. Clin Exp Rheumatol 2008; 26: 35-40.
43. Rothenberg ME, Klion AD, Roufosse FE. Treamtent of patients with the hypereosinophilic syndrome with Mepolizumab. N Engl J Med 2008; 358: 1215-1238.